article thumbnail

An Orbimed-backed biotech launches with $85M and plans for a new kind of DNA medicine

Bio Pharma Dive

Rampart Biosciences closed a Series A round that will fund its goal to develop more potent DNA-based medicines that avoid immune responses.

DNA 267
article thumbnail

Charles Eger, MD, Authors New Article in Nature Medicine

Velocity Clinical Research

Early results from the Phase 1/2 trial show that the vaccine is well-tolerated and induces strong immune responses, potentially paving the way for a more convenient approach to respiratory virus prevention.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nature article: SARS-CoV-2 disrupts timing of immune response

Scienmag

to downgrade its immune response. In severe COVID-19, however, this messenger is released at the very beginning of the infection, thus blocking the early control of the pathogen by the innate immune system. Once an infection is under control, the body normally uses a biochemical messenger known as TGF?

article thumbnail

Long-term immune response to SARS-CoV-2 mRNA vaccination found to be unaffected by pregnancy

Medical Xpress

Within a study by investigators at Weill Cornell Medicine and NewYork-Presbyterian, the long-term immune response to SARS-CoV-2 mRNA vaccination was similar in pregnant individuals and non-pregnant individuals of reproductive age.

article thumbnail

Malaysia approves additional indication for Astrazeneca’s Evusheld

Pharmaceutical Technology

It will also be used for the treatment of people who are not likely to have an adequate immune response to Covid-19 vaccination or for people who are not recommended for Covid-19 vaccination. Dr Noor Hisham was quoted as saying: “The use of Evusheld was based on clinical guidelines issued by the health ministry.”

article thumbnail

The Lancet Respiratory Medicine: Clinical trial finds inhaled immune response protein increases odds of recovery for hospitalised COVID-19 patients

Scienmag

Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.

article thumbnail

Scientists blueprint bacterial enzyme believed to “stealthily” suppress immune response

Scienmag

Scientists have produced the first fine-detail molecular blueprints of a bacterial enzyme known as Lit, which is suspected to play a “stealthy” role in the progression of infection by reducing the immune response.